coronavirus
cov
belong
subfamili
othocoronavirina
famili
coronavirida
order
nidoviral
accord
report
viru
taxonomi
intern
committe
taxonomi
virus
ictv
othocoronavirina
compris
four
genera
includ
alphacoronaviru
alphacov
betacoronaviru
betacov
gammacoronaviru
gammacov
deltacoronaviru
deltacov
king
et
al
alpha
betacov
infect
mammal
includ
limit
bat
pig
cat
mice
human
kusanagi
et
al
li
et
al
poon
et
al
drexler
et
al
pedersen
kudelova
et
al
cui
et
al
gamma
deltacov
usual
infect
bird
could
infect
mammal
woo
et
al
et
al
sinc
late
sixti
cov
recogn
one
viral
sourc
respons
common
cold
among
cov
identifi
far
seven
abil
infect
human
includ
human
coronaviru
human
coronaviru
belong
alphacov
hamr
procknow
chiu
et
al
well
human
coronaviru
human
coronaviru
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
newli
emerg
coronaviru
known
betacov
drosten
et
al
ksiazek
et
al
vabret
et
al
woo
et
al
zaki
et
al
du
et
al
zhang
et
al
zhu
et
al
figur
four
human
cov
includ
identifi
human
without
caus
sever
infect
isol
nasal
secret
medic
student
minor
upper
respiratori
diseas
viru
origin
isol
first
report
hamr
procknow
addit
sever
studi
report
recoveri
patient
upper
respiratori
tract
ill
tyrrel
byno
hamr
et
al
mcintosh
et
al
kapikian
et
al
isol
clinic
speci
infant
suffer
pneumonia
bronchiol
character
abil
infect
human
respiratori
tract
fouchier
et
al
van
der
hoek
et
al
subsequ
studi
identifi
new
member
cov
name
man
pneumonia
woo
et
al
gener
four
virus
common
pathogen
caus
mild
upper
respiratori
infect
asymptomat
infect
count
cold
myint
lau
et
al
kim
et
al
serolog
surveil
healthi
adult
demonstr
seroposit
immunolog
assay
appear
common
cov
infect
children
mourez
et
al
shao
et
al
sever
et
al
contrast
three
human
cov
around
seroposit
healthi
individu
rel
low
exposur
rate
children
lehmann
et
al
sever
et
al
although
preval
variou
cov
differ
incid
among
virus
show
signific
differ
woo
et
al
aforement
four
cov
detect
clinic
specimen
esper
et
al
lau
et
al
gerna
et
al
regamey
et
al
matoba
et
al
killerbi
et
al
virus
also
associ
lower
respiratori
tract
ill
children
elder
immunodefici
individu
falsey
et
al
fouchier
et
al
woo
et
al
gerna
et
al
may
lead
central
nervou
system
infect
sinc
viral
rna
detect
brain
patient
arbour
et
al
desforg
et
al
unlik
four
human
cov
sarscov
merscov
caus
sever
pneumonia
andor
failur
organ
even
death
among
infect
popul
nichol
et
al
zhong
et
al
zaki
et
al
zhu
et
al
epidem
outbreak
sarscov
began
guangdong
provinc
china
novemb
spread
humantohuman
transmiss
part
world
within
month
ksiazek
et
al
novemb
august
sarscov
infect
peopl
counti
result
death
fatal
rate
du
et
al
palm
civet
serv
potenti
intermedi
host
viru
trace
immedi
tu
et
al
chines
horsesho
bat
rhinolophu
sinicu
natur
reservoir
sarscov
li
et
al
variou
bat
sarsrel
cov
sarsrcov
identifi
yunnan
china
sever
infect
human
cell
character
ge
et
al
hu
et
al
discoveri
indic
threat
reemerg
sarscov
sarsrcov
decad
later
anoth
highli
pathogen
human
cov
merscov
emerg
first
patient
merscov
infect
report
saudi
arabia
june
zaki
et
al
decemb
total
laboratoryconfirm
case
mer
includ
associ
death
countri
fatal
rate
report
global
major
human
case
report
saudi
arabia
peopl
get
infect
direct
contact
infect
dromedari
camel
zaki
et
al
isol
merscov
detect
neutral
antibodi
dromedari
camel
suggest
camel
potenti
import
intermedi
host
reusken
et
al
azhar
et
al
similar
sarscov
merscov
also
emerg
zoonot
viru
li
du
bat
habitu
sever
cov
phylogenet
relat
merscov
ident
merscov
suggest
merscov
may
origin
bat
annan
et
al
lelli
et
al
lau
et
al
luo
et
al
differ
sarscov
caus
infect
human
sinc
du
et
al
transmiss
merscov
interrupt
infect
human
case
continu
mobaraki
ahmadzadeh
current
humantohuman
transmiss
merscov
limit
new
cov
caught
worldwid
attent
liu
saif
zhang
et
al
first
identifi
wuhan
china
decemb
patient
pneumonia
zhu
et
al
infect
peopl
global
includ
death
fatal
rate
februari
particularli
china
part
world
includ
australia
japan
malaysia
singapor
south
korea
viet
nam
cambodia
philippin
thailand
nepal
sri
lanka
india
unit
state
canada
franc
finland
germani
itali
russian
feder
spain
sweden
unit
kingdom
belgium
egypt
unit
arab
differ
merscov
similar
sarscov
caus
humantohuman
transmiss
intermedi
host
lead
current
human
infect
outbreak
still
investig
human
cov
envelop
virus
positivesens
singlestrand
rna
genom
nm
diamet
like
cov
human
cov
contain
largest
viral
genom
kilobas
pair
kb
among
rna
virus
share
similar
genom
organ
fehr
perlman
two
larg
overlap
open
read
frame
orf
orf
orf
occupi
twothird
genom
third
genom
encod
four
common
structur
protein
gene
order
spike
envelop
e
membran
nucleocapsid
n
fehr
perlman
larg
orf
replicas
gene
encod
polyprotein
cleav
nonstructur
protein
proteinas
papainlik
proteinas
plpro
baileyelkin
et
al
fehr
perlman
tomar
et
al
snijder
et
al
addit
gene
encod
structur
protein
gene
encod
accessori
protein
also
detect
region
fehr
perlman
betacov
contain
hemagglutininesteras
gene
locat
orf
gene
encod
addit
structur
protein
de
groot
et
al
desforg
et
al
huang
et
al
similar
human
cov
sarscov
possess
genom
encod
four
main
structur
protein
e
n
eight
accessori
protein
figur
marra
et
al
snijder
et
al
merscov
genom
kb
length
encod
four
structur
protein
e
n
five
accessori
protein
figur
van
boheemen
et
al
genom
rna
sarscov
merscov
pack
insid
capsid
form
n
protein
e
protein
form
envelop
surround
capsid
figur
accessori
gene
may
incorpor
virion
low
level
liu
et
al
nevertheless
neither
sarscov
merscov
appear
contain
gene
rota
et
al
zaki
et
al
sever
protein
human
cov
import
viral
infect
andor
pathogenesi
exampl
nsp
particip
viral
rna
replic
andor
transcript
snijder
et
al
accessori
protein
interact
host
cell
potenti
help
virus
evad
immun
system
increas
virul
menacheri
et
al
protein
assist
attach
cell
thu
play
key
role
product
infecti
virion
case
desforg
et
al
e
protein
respons
viru
assembl
promot
virul
scobey
et
al
dediego
et
al
differ
protein
protein
human
cov
mediat
viral
entri
host
cell
subsequ
membran
fusion
enabl
viral
infect
du
et
al
lu
et
al
protein
class
viral
protein
cleav
two
function
subunit
aminotermin
subunit
carboxyltermin
subunit
subunit
respons
cell
receptor
bind
wherea
subunit
involv
membran
fusion
li
et
al
lu
et
al
contain
two
major
domain
ntermin
domain
ntd
ctermin
domain
ctd
gener
ntd
mediat
sugar
bind
li
li
et
al
ou
et
al
hulswit
et
al
tortorici
et
al
wherea
ctd
facilit
protein
receptor
recognit
wong
et
al
hofmann
et
al
lu
et
al
ntd
ctd
subunit
bind
host
receptor
function
receptorbind
domain
rbd
lu
et
al
hulswit
et
al
entri
human
cov
reli
interact
viral
cellular
membran
protein
recognit
subunit
receptor
andor
sugar
cell
surfac
initi
infect
li
initi
recognit
bind
protein
undergo
conform
chang
follow
membran
fusion
region
li
du
et
al
consequ
viral
genet
materi
deliv
host
cell
fusion
core
du
et
al
similar
hofmann
et
al
li
sarscov
recogn
rbd
ctd
region
subunit
angiotensinconvert
enzym
receptor
target
cell
li
et
al
rbd
ctd
two
state
stand
lie
observ
trimer
protein
bind
stand
rbd
specif
receptorbind
motif
rbm
keep
rbd
stand
state
yuan
et
al
addit
human
sarscov
protein
could
also
bind
palm
civet
mous
li
et
al
li
mutat
rbd
subunit
requir
crossspeci
transmiss
sarscov
li
et
al
li
sever
bat
sarsrcov
identifi
cov
util
human
receptor
bind
target
cell
ge
et
al
hu
et
al
structur
sarscov
trimer
rbd
bind
receptor
shown
supplementari
figur
b
merscov
rbd
share
structur
similar
homolog
domain
sarscov
wang
et
al
howev
antibodi
induc
sarscov
rbd
crossreact
andor
crossneutr
activ
merscov
du
et
al
moreov
merscov
util
dipeptidyl
peptidas
receptor
rbd
ctd
region
raj
et
al
distinct
sarscov
receptor
although
core
region
sarscov
merscov
rbd
similar
rbm
region
significantli
differ
explain
recogn
differ
receptor
li
merscov
trimer
also
maintain
structur
similar
sarscov
trimer
stand
lie
state
detect
merscov
rbd
wherea
bind
stand
rbd
pallesen
et
al
yuan
et
al
merscov
cluster
tybatcov
pibatcov
subgenu
merbecoviru
tybatcov
pibatcov
could
use
human
receptor
yang
et
al
recent
mersrel
cov
mersrcov
discov
bat
enter
human
cell
lau
et
al
luo
et
al
find
suggest
emerg
mersrcov
may
threaten
human
health
owe
potenti
crossspeci
transmiss
merscov
protein
rbd
complex
along
receptor
shown
supplementari
figur
recent
studi
found
new
human
cov
belong
speci
sarsrcov
share
high
sequenc
identifi
sarscov
zhou
et
al
genom
encod
translat
orf
four
structur
protein
e
n
six
accessori
protein
figur
sarscov
merscov
appear
gene
virion
consist
similar
structur
sarscov
merscov
figur
like
sarscov
also
use
cellular
receptor
enter
host
cell
zhou
et
al
current
structur
rbd
andor
bind
viral
receptor
yet
avail
unlik
four
low
pathogen
human
cov
includ
caus
mild
pathogenesi
human
sarscov
merscov
three
highli
pathogen
human
cov
channappanavar
perlman
cui
et
al
zhu
et
al
increas
number
merscov
infect
continu
threat
reemerg
sarscov
well
potenti
sar
mersrel
cov
caus
human
infect
critic
develop
vaccin
strong
efficaci
safeti
target
virus
prevent
infect
human
sinc
vaccin
avail
rest
review
focu
vaccin
sarscov
merscov
although
varieti
vaccin
develop
sarscov
merscov
preclin
studi
sever
test
clinic
du
et
al
cho
et
al
nevertheless
vaccin
approv
prevent
sar
mer
human
demonstr
need
develop
effect
safe
vaccin
control
current
merscov
infect
stockpil
potenti
use
reemerg
sarscov
sarsrcov
particularli
effect
safe
vaccin
urgent
need
prevent
control
current
outbreak
sarscov
merscov
vaccin
develop
thu
far
base
inactiv
live
attenu
virus
dna
protein
nanoparticl
viral
vector
includ
viruslik
particl
vlp
zeng
et
al
jiang
et
al
liu
et
al
du
et
al
pimentel
et
al
alamri
et
al
vaccin
type
differ
advantag
disadvantag
instanc
inactiv
liveattenu
virusbas
vaccin
vaccin
type
develop
use
tradit
approach
although
gener
induc
highli
potent
immun
respons
andor
protect
possibl
incomplet
inactiv
virus
recov
virul
exist
result
signific
safeti
concern
zhang
et
al
also
tradit
vaccin
may
induc
antibodydepend
enhanc
ade
effect
case
sarscov
infect
luo
et
al
similarli
viralvector
vaccin
elicit
specif
antibodi
cellular
immun
respons
neutral
activ
protect
might
also
induc
antivector
immun
present
preexist
immun
caus
harm
immun
respons
instead
dna
nanoparticl
vaccin
maintain
strong
safeti
profil
howev
immunogen
vaccin
usual
lower
viru
viral
vectorbas
vaccin
often
requir
optim
sequenc
compon
immun
rout
inclus
appropri
adjuv
applic
combin
immun
approach
zhang
et
al
protein
sarscov
merscov
play
vital
role
receptor
bind
membran
fusion
thu
protein
structur
protein
major
antigen
induc
protect
neutral
antibodi
block
virus
bind
respect
receptor
thu
inhibit
viral
infect
bisht
et
al
buchholz
et
al
bukreyev
et
al
yang
et
al
result
protein
also
major
target
develop
subunit
vaccin
sarscov
merscov
fulllength
protein
antigen
fragment
includ
subunit
ntd
rbd
subunit
serv
import
target
develop
subunit
vaccin
guo
et
al
mou
et
al
wang
et
al
jiam
et
al
zhou
et
al
although
subunit
vaccin
base
fulllength
protein
may
elicit
potent
immun
respons
andor
protect
studi
found
antibodi
induc
vaccin
mediat
enhanc
viral
infect
vitro
case
sarscov
kam
et
al
jaum
et
al
rais
safeti
concern
develop
fulllength
proteinbas
subunit
vaccin
sarscov
merscov
contrast
rbdbase
subunit
vaccin
compris
major
critic
neutral
domain
du
jiang
zhou
et
al
therefor
vaccin
may
gener
potent
neutral
antibodi
strong
protect
immun
viral
infect
subunit
exampl
much
shorter
fulllength
protein
less
abl
induc
strong
immun
respons
andor
protect
viral
infect
li
et
al
adney
et
al
thu
fragment
use
altern
target
subunit
vaccin
develop
despit
abil
induc
immun
respons
andor
neutral
antibodi
ntd
target
subunit
vaccin
less
immunogen
elicit
significantli
lower
antibodi
titer
cellular
immun
respons
andor
protect
region
fulllength
rbd
guo
et
al
jiam
et
al
therefor
term
safeti
efficaci
rbd
andor
protein
could
appli
critic
target
develop
subunit
vaccin
candid
sarscov
merscov
sarsrcov
mersrcov
conserv
amino
acid
sequenc
high
homolog
among
differ
viru
strain
elshabrawi
et
al
zhou
et
al
subunit
potenti
use
target
develop
univers
vaccin
diverg
viru
strain
addit
protein
n
protein
sarscov
merscov
may
serv
addit
target
develop
subunit
vaccin
unlik
protein
n
protein
abil
elicit
neutral
antibodi
block
virusreceptor
interact
neutral
viral
infect
may
induc
specif
antibodi
cellular
immun
respons
liu
et
al
zheng
et
al
sever
immunodomin
bcell
tcell
epitop
identifi
n
protein
sarscov
merscov
conserv
mice
nonhuman
primat
human
liu
et
al
chan
et
al
veit
et
al
protein
protein
use
potenti
target
sarscov
merscov
subunit
vaccin
notabl
sarscov
proteinderiv
peptid
immunogen
induc
hightit
antibodi
respons
immun
anim
et
al
suggest
potenti
util
protein
develop
subunit
vaccin
subunit
vaccin
base
sarscov
protein
includ
fulllength
trimer
protein
immunogen
protect
sarscov
infect
et
al
kam
et
al
li
et
al
either
insect
cellexpress
fulllength
fl
extracellular
domain
ec
sarscov
protein
develop
hightit
sspecif
antibodi
neutral
activ
pseudotyp
sarscov
express
protein
repres
sarscov
human
palm
civet
strain
isol
outbreak
et
al
addit
fulllength
sectodomain
protein
fuse
without
foldon
trimer
motif
sfoldon
could
elicit
specif
antibodi
respons
neutral
antibodi
protect
immun
mice
sarscov
challeng
undetect
viru
titer
lung
li
et
al
moreov
subunit
vaccin
trispik
base
fulllength
protein
trimer
induc
specif
serum
mucos
antibodi
respons
effici
neutral
antibodi
sarscov
infect
kam
et
al
nevertheless
vaccin
also
result
receptor
ii
depend
ade
particularli
human
monocyt
lymphoblast
cell
line
infect
pseudotyp
sarscov
express
viral
protein
raji
b
cell
bcell
lymphoma
line
infect
live
sarscov
kam
et
al
jaum
et
al
rais
signific
concern
use
fulllength
protein
sar
vaccin
target
sarscov
rbd
contain
multipl
conformationdepend
epitop
capabl
elicit
hightit
neutral
antibodi
thu
major
target
develop
sar
vaccin
et
al
jiang
et
al
zhu
et
al
subunit
vaccin
base
sarscov
rbd
extens
explor
studi
found
fusion
protein
contain
rbd
fragment
crystalliz
fc
region
human
rbdfc
elicit
highli
potent
neutral
antibodi
sarscov
immun
rabbit
mice
strongli
block
bind
protein
sarscov
receptor
et
al
rbd
protein
induc
longterm
highlevel
sarscov
sspecif
antibodi
neutral
antibodi
could
maintain
month
immun
protect
vaccin
mice
sarscov
infect
du
et
al
addit
recombin
rbd
residu
stabli
transient
express
chines
hamster
ovari
cho
cell
bound
strongli
rbdspecif
monoclon
antibodi
mab
elicit
hightit
antisarscov
neutral
antibodi
protect
sarscovchalleng
mice
undetect
viral
rna
undetect
significantli
reduc
viral
load
du
et
al
significantli
cellexpress
rbd
protein
maintain
excel
conform
good
antigen
bind
sarscov
rbdspecif
neutral
mab
elicit
highli
potent
neutral
antibodi
complet
protect
immun
mice
sarscov
challeng
du
et
al
particularli
rbd
protein
repres
strain
sarscov
isol
human
palm
civet
strain
induc
hightit
crossneutr
antibodi
pseudotyp
sarscov
express
respect
protein
et
al
differ
fulllength
proteinbas
sar
subunit
vaccin
obviou
pathogen
effect
identifi
rbdbase
sar
subunit
vaccin
kam
et
al
jaum
et
al
sar
subunit
vaccin
base
protein
fragment
rbd
shown
immunogen
andor
protect
efficaci
sarscov
infect
guo
et
al
li
et
al
exampl
recombin
protein
fuse
without
foldon
elicit
specif
antibodi
neutral
activ
protect
immun
mice
highdos
sarscov
challeng
li
et
al
although
studi
demonstr
recombin
sarscov
residu
protein
elicit
specif
nonneutr
antibodi
respons
mice
guo
et
al
other
indic
mab
target
highli
conserv
heptad
repeat
domain
sarscov
protein
broad
neutral
activ
pseudotyp
sarscov
express
protein
diverg
strain
elshabrawi
et
al
indic
potenti
util
region
broadspectrum
antisarscov
vaccin
target
zheng
et
al
subunit
vaccin
base
n
protein
sarscov
shown
immunogen
vaccin
anim
liu
et
al
zheng
et
al
studi
reveal
plantexpress
sarscov
n
protein
conjug
freund
adjuv
elicit
specif
igg
antibodi
includ
subtyp
cellular
immun
respons
mice
wherea
anoth
e
coliexpress
n
protein
conjug
montanid
cysteinephosphateguanin
cpg
adjuv
induc
specif
igg
antibodi
toward
type
respons
mice
liu
et
al
zheng
et
al
although
nspecif
antibodi
detect
convalescentphas
sar
patient
immun
rabbit
sera
neutral
activ
sarscov
infect
qiu
et
al
addit
immunodomin
protein
peptid
identifi
use
convalescentphas
sera
sar
patient
immun
mous
rabbit
sera
immunogen
elicit
specif
igg
antibodi
rabbit
et
al
spite
immunogen
appear
n
mbase
sar
subunit
vaccin
investig
protect
efficaci
sarscov
infect
thu
unclear
whether
non
structur
proteinbas
sar
subunit
vaccin
prevent
sarscov
infect
number
factor
may
affect
express
protein
use
sar
subunit
vaccin
apart
immunogen
andor
protect
efficaci
understand
factor
import
gener
subunit
vaccin
good
qualiti
high
immunogen
excel
protect
sarscov
infect
express
recombin
proteinbas
sar
subunit
vaccin
may
chang
follow
factor
first
addit
intron
splice
enhanc
truncat
sarscov
protein
fragment
result
better
enhanc
protein
express
mammalian
cell
exon
splice
enhanc
differ
cell
may
result
differ
fold
increas
protein
express
chang
et
al
second
inclus
posttranscript
gene
silenc
suppressor
protein
tomato
bushi
stunt
viru
sarscov
n
protein
may
significantli
increas
transient
express
tobacco
zheng
et
al
follow
factor
may
affect
immunogen
protect
efficaci
proteinbas
sar
subunit
vaccin
includ
protein
express
differ
express
system
protein
variou
length
amino
acid
mutat
delet
et
al
du
et
al
exampl
rbd
protein
contain
differ
length
elicit
differ
immun
respons
protect
efficaci
sarscov
challeng
du
et
al
recombin
sarscov
rbd
protein
express
mammalian
cell
system
abl
induc
stronger
neutral
antibodi
respons
express
insect
cell
e
coli
rbdec
du
et
al
suggest
rbd
purifi
mammalian
cell
prefer
develop
due
abil
maintain
nativ
conform
notabl
singl
mutat
rbd
sarscov
disrupt
major
neutral
epitop
affin
bind
viral
receptor
thu
abolish
vaccin
immunogen
henc
abil
induc
neutral
antibodi
immun
anim
et
al
addit
delet
particular
amino
acid
chang
glycosyl
site
sarscov
rbd
also
result
alter
subunit
vaccin
immunogen
chen
et
al
factor
potenti
affect
immunogen
sar
subunit
vaccin
includ
immun
rout
adjuv
zakhartchouk
et
al
li
et
al
significantli
hightit
antibodi
induc
monomer
trimer
sarscov
protein
intramuscular
im
rout
compar
subcutan
sc
rout
li
et
al
moreov
sarscov
rbd
subunit
vaccin
conjug
alum
plu
cpg
adjuv
elicit
higher
level
antibodi
interferon
gamma
secret
rbd
alum
alon
zakhartchouk
et
al
subunit
vaccin
base
fulllength
protein
cover
rbd
nonrbd
neutral
epitop
may
locat
conserv
subunit
thu
type
subunit
vaccin
expect
induc
hightit
neutral
antibodi
although
sever
merscov
fulllength
proteinbas
vaccin
report
vaccin
type
includ
viral
vector
dna
wang
et
al
wang
c
et
al
haagman
et
al
zhou
et
al
subunit
vaccin
develop
reli
fulllength
protein
exampl
recombin
merscov
protein
trimer
mer
prefus
conform
bind
receptor
well
merscov
ntd
rbd
neutral
mab
pallesen
et
al
wherea
protein
induc
neutral
antibodi
mice
diverg
pseudotyp
merscov
vitro
vivo
protect
activ
merscov
infect
unknown
pallesen
et
al
therefor
studi
need
elucid
potenti
develop
merscov
fulllength
sbase
subunit
vaccin
includ
understand
protect
efficaci
identifi
possibl
harm
immun
respons
numer
merscov
rbdbase
subunit
vaccin
develop
extens
evalu
avail
anim
model
sinc
emerg
merscov
tabl
du
et
al
tai
et
al
zhou
et
al
gener
subunit
vaccin
strong
immunogen
capabl
induc
high
neutral
antibodi
andor
protect
merscov
infect
et
al
zhang
et
al
tai
et
al
wang
et
al
subunit
vaccin
base
merscov
rbd
describ
detail
previou
review
articl
zhou
et
al
section
briefli
introduc
rbdtarget
mer
vaccin
compar
function
antigen
immunogen
protect
merscov
infect
cocrystallograph
analys
merscov
rbd
andor
complex
confirm
rbd
attribut
residu
chen
et
al
lu
et
al
merscov
subunit
inde
recombin
merscov
rbd
rrbd
fragment
residu
elicit
rbdspecif
antibodi
cellular
immun
respons
neutral
antibodi
mice
andor
nonhuman
primat
nhp
lan
et
al
howev
partial
protect
nhp
merscov
infect
allevi
pneumonia
clinic
manifest
well
decreas
viral
load
lan
et
al
addit
rbd
protein
fragment
contain
merscov
residu
fuse
fc
tag
human
igg
induc
merscov
andor
rbdspecif
humor
cellular
immun
respons
immun
mice
neutral
activ
merscov
infect
du
et
al
jiang
et
al
howev
compar
sever
version
merscov
rbd
fragment
differ
length
found
truncat
rbd
residu
highest
affin
induc
highesttit
igg
antibodi
neutral
antibodi
merscov
identifi
role
critic
neutral
domain
et
al
subsequ
sever
merscov
subunit
vaccin
design
base
identifi
critic
neutral
domain
rbd
fragment
includ
express
stabl
cho
cell
line
fuse
trimer
motif
foldon
rbdfd
contain
singl
multipl
mutat
rbd
repres
human
camel
strain
mer
outbreak
tai
et
al
nyon
et
al
rbd
protein
maintain
good
conform
function
antigen
immunogen
abil
bind
receptor
rbdspecif
neutral
mab
elicit
robust
neutral
antibodi
crossneutr
multipl
strain
mer
pseudovirus
live
merscov
tai
et
al
nyon
et
al
note
wildtyp
merscov
rbd
protein
consist
identifi
critic
neutral
domain
confer
partial
protect
mice
merscov
infect
without
caus
immunolog
toxic
eosinophil
immun
enhanc
tai
et
al
wang
et
al
nyon
et
al
nevertheless
structur
design
mutant
version
rbd
protein
nonneutr
epitop
mask
preserv
intact
conform
significantli
improv
overal
neutral
activ
protect
efficaci
result
full
protect
mice
highdos
merscov
challeng
du
et
al
studi
indic
protein
length
chosen
merscov
subunit
vaccin
andor
structurebas
vaccin
design
impact
immunogen
andor
protect
rbdbase
subunit
vaccin
mer
vaccin
target
nonrbd
region
protein
develop
investig
mice
nhp
shown
merscov
protein
formul
ribi
mice
aluminum
phosphat
nhp
adjuv
elicit
robust
neutral
antibodi
mice
nhp
diverg
strain
pseudotyp
live
merscov
protect
nhp
merscov
infect
wang
et
al
addit
merscov
protein
adjuv
advax
sigma
adjuv
system
induc
lowtit
neutral
antibodi
dromedari
camel
reduc
delay
viral
shed
merscov
challeng
hightit
neutral
antibodi
alpaca
complet
protect
viral
shed
viral
infect
indic
protect
merscov
infect
posit
correl
serum
neutral
antibodi
titer
adney
et
al
moreov
immun
recombin
merscov
ntd
protein
rntd
induc
neutral
antibodi
cellmedi
respons
protect
mice
merscov
challeng
jiam
et
al
notabl
specif
antibodi
neutral
activ
elicit
peptid
sequenc
residu
merscov
rabbit
yang
et
al
protect
efficaci
peptid
vaccin
unknown
report
demonstr
potenti
develop
mer
subunit
vaccin
base
nonrbd
fragment
merscov
protein
unlik
sar
subunit
vaccin
design
base
viral
n
protein
appear
subunit
vaccin
develop
base
non
structur
protein
merscov
one
studi
report
induct
specif
antibodi
merscov
n
peptid
yang
et
al
anoth
report
show
n
protein
use
develop
vaccin
base
viral
vector
vaccinia
viru
modifi
vaccinia
ankara
mva
veit
et
al
may
potenti
consequ
weak
immunogen
andor
protect
efficaci
non
structur
protein
confirm
role
merscov
protein
key
target
develop
mer
vaccin
includ
subunit
vaccin
similar
sarscov
subunit
vaccin
immunogen
andor
protect
merscov
subunit
vaccin
may
also
affect
number
factor
antigen
sequenc
fragment
length
adjuv
vaccin
pathway
antigen
dose
immun
dose
interv
use
describ
merscov
subunit
vaccin
contain
differ
antigen
fragment
length
particularli
base
rbd
appar
variabl
immunogen
andor
protect
efficaci
critic
neutral
domain
contain
rbd
fragment
correspond
residu
protein
elicit
highest
neutral
antibodi
among
sever
fragment
test
et
al
zhang
et
al
adjuv
play
essenti
role
enhanc
host
immun
respons
merscov
subunit
vaccin
includ
base
rbd
differ
adjuv
promot
host
immun
respons
variant
level
lan
et
al
zhang
et
al
exampl
merscov
rbd
subunit
vaccin
protein
fuse
fc
alon
induc
detect
neutral
antibodi
tcell
respons
immun
mice
inclus
adjuv
enhanc
immunogen
particularli
among
adjuv
freund
aluminum
monophosphoryl
lipid
montanid
conjug
rbd
protein
could
best
potenti
protein
induc
highesttit
anti
antibodi
neutral
antibodi
protect
mice
merscov
infect
zhang
et
al
moreov
recombin
rbd
rrbd
protein
plu
alum
cpg
adjuv
elicit
highest
neutral
antibodi
pseudotyp
merscov
infect
wherea
strongest
tcell
respons
induc
protein
plu
freund
cpg
adjuv
lan
et
al
vaccin
pathway
import
induc
effici
immun
respons
differ
immun
rout
may
elicit
differ
immun
respons
protein
antigen
exampl
immun
mice
merscov
subunit
vaccin
rbdfc
via
intranas
rout
induc
higher
level
cellular
immun
respons
stronger
local
mucos
neutral
antibodi
respons
merscov
infect
induc
vaccin
via
sc
pathway
et
al
addit
freund
cpgadjuv
rrbd
protein
elicit
higherlevel
systemat
local
cell
via
sc
rout
protein
adjuv
alum
cpg
induc
higherlevel
tumor
necrosi
factoralpha
interleukin
secret
cell
via
im
rout
lan
et
al
antigen
dosag
immun
dose
interv
may
significantli
affect
immunogen
merscov
subunit
vaccin
notabl
merscov
rbd
subunit
vaccin
immun
elicit
strong
humor
cellular
immun
respons
neutral
antibodi
mice
although
one
immun
elicit
higher
level
antibodi
tang
et
al
addit
among
regimen
one
dose
two
dose
interv
dose
protein
boost
week
result
highest
antibodi
neutral
antibodi
merscov
infect
wang
et
al
compar
vaccin
type
inactiv
viru
viralvector
vaccin
sar
mer
subunit
vaccin
much
safer
caus
obviou
side
effect
howev
subunit
vaccin
may
face
import
challeng
mostli
aris
rel
low
immunogen
must
combin
appropri
adjuv
optim
suitabl
protein
sequenc
fragment
length
immun
schedul
addit
structur
epitopebas
vaccin
design
becom
promis
strategi
improv
efficaci
subunit
vaccin
evidenc
structur
design
merscov
rbdbase
protein
significantli
improv
neutral
activ
protect
merscov
infect
du
et
al
prospect
structureguid
novel
strategi
develop
improv
overal
immunogen
efficaci
subunit
vaccin
emerg
pathogen
human
coronavirus
includ
target
sarscov
merscov
although
larg
number
sar
mer
subunit
vaccin
develop
potent
immunogen
andor
protect
avail
anim
model
virtual
remain
preclin
stage
thu
expect
one
sever
promis
subunit
vaccin
process
clinic
trial
confirm
immunogen
viral
infect
human
current
newli
identifi
spread
infect
peopl
result
signific
global
concern
critic
rapidli
design
develop
effect
vaccin
prevent
infect
new
coronaviru
sinc
protein
fragment
rbd
sarscov
merscov
prime
target
develop
subunit
vaccin
two
highli
pathogen
human
cov
expect
similar
region
also
use
key
target
develop
vaccin
new
coronaviru
jiang
et
al
similarli
region
includ
subunit
protein
n
protein
appli
altern
target
vaccin
develop
taken
togeth
approach
strategi
develop
subunit
vaccin
sar
mer
describ
review
provid
import
inform
rapid
design
develop
safe
effect
subunit
vaccin
infect
sj
ld
conceiv
idea
revis
edit
manuscript
nw
ld
collect
inform
draft
manuscript
js
perform
structur
analysi
author
read
made
final
approv
manuscript
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
